We're supporting people to maintain their wellbeing and manage isolation.
As part of the NHMRC Motor Impairment grant we are investigating the role that sleep disruption plays in people with Multiple Sclerosis.
This project, sponsored by MS research Australia, focuses on sleep apnoea in people with multiple sclerosis (MS). Our recent study, amongst other studies, suggests that sleep apnoea rates are higher in people with MS. However little is known about the causes of sleep apnoea in people with MS and how they might be different from people without MS. This project involves a sleep study including physiological measurements to identify differences in the causes of sleep apnoea between people with and without MS.
Obstructive sleep apnoea (OSA) is a common disorder characterised by repetitive narrowing and collapse of the upper airway during sleep. It is associated with daytime sleepiness, neurocognitive impairment, and a variety of adverse cardiovascular consequences. The first line treatment for OSA is continuous positive airway pressure (CPAP) therapy. If tolerated, CPAP is highly effective in reducing sleep disordered breathing events. However, up to 50% of OSA patients are unable to tolerate CPAP therapy leaving many OSA patients without treatment.
Previous studies indicate that in selected obstructive sleep apnea participants a standard dose of a z-drug can shift the threshold for awakening during sleep (arousal) whilst maintaining the upper airway muscle activity required to keep the airway open. This study aims to investigate the effects of different doses of sleeping pills (Z-drugs) on how easily people wake up when the airway narrows during sleep, the activity of a major muscle located under the tongue (genioglossus) and obstructive sleep apnoea (OSA) severity and symptoms.